Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer

Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2011.0146


Cetuximab: Explaining resistance and disappointing new results

Prof. Dr. Med Christof Hottenrott, M.D.

Affiliation: Prof. Dr. Med Christof Hottenrott, Chirurgische Klinik St. Elisabethenkrankenhaus Ginnheimer Straße 3, 60487, Frankfurt .


Cetuximab a monoclonal antibody against EGFR- has been approved for the treatment of KRAS wild-type metastatic colorectal cancer (mCRC). However, new results from phase III randomized controlled trials (RCTs) presented in the 2010 ASCO meeting arise serious concerns on the clinical utility of adding cetuximab to standard chemotherapy. For the first time results from a large RCT with cetuximab treatment in the adjuvant setting, become available. In the metastatic setting, the results of a new RCT are in contrast with previous RCTs that had showed an overall survival benefit with cetuximab in KRAS wild-type mCRC. Can these RCTs be considered as practice-changing studies? How can be explained the resistance and failure of cetuximab in both adjuvant and metastatic setting of CRC?

(Citation: Gastric & Breast Cancer 2011; 10(1): 25-29)

You can have an online full-text access and a PDF of this article:
  • Either purchase this paper for €33 EUR. Please, click here
Please specify DOI of article
  • Or through one year subscription PayPal

Online ISSN : 1109 - 7647
Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 8 February 2011